NY-NORSK-TITANIUM-AS
Norsk Titanium AS (Euronext: NTI, OTCQB: NORSF) is pleased to announce that it has obtained approval for trading on the OTCQB market and commenced trading under the ticker “NORSF”. By joining OTCQB market, the company further enhances its North American presence and commitment to U.S. customers and investors.
Norsk Titanium is a global leader in metal 3D printing through its Rapid Plasma Deposition® (RPD® ) technology and industrial scale production in the highly regulated Commercial Aerospace industry. Headquartered in Norway, Norsk Titanium entered the public marketplace in 2021 by listing on the Euronext Growth exchange.
“We are excited to start trading our shares on the OTCQB Venture Market,” said Michael Canario, CEO of Norsk Titanium. “This is a natural progression of our vision to broaden our investor base and expand our presence in North America where our state-of-the-art 640 metric tons additive manufacturing production facilities are located.”
“Norsk Titanium is poised to enter a period of significant growth, offering cost-efficient and value-adding 3D printed parts to a large addressable market,” adds Canario. With its additively manufactured RPD® parts already in serial production for the Boeing 787 Dreamliner, Norsk Titanium is now developing parts for the Airbus A350, US defense market prime contractors, and the industrial market.
The OTCQB is operated by the OTC Markets Group and recognized by the Securities and Exchange Commission (SEC) as an established public market providing data that investors need to analyze, value and trade securities. Being part of the OTC Markets Group will assist in diversifying Norsk Titanium’s shareholder base with increased liquidity and brand visibility while maintaining a high level of transparency to inform and engage investors.
More information about OTCQB requirements and standards can be found at:
https://www.otcmarkets.com/corporate-services/get-started/otcqb
.
ABOUT NORSK TITANIUM
Norsk Titanium is a global leader in metal 3D printing, innovating the future of metal manufacturing by enabling a paradigm shift to a clean and sustainable manufacturing process. With its proprietary Rapid Plasma Deposition®
(RPD®
) technology and 700 MT of production capacity, Norsk Titanium offers cost-efficient 3D printing of value-added metal parts to a large addressable market. The RPD®
technology uses significantly less raw material, energy, and time than traditional energy-intensive forming methods, presenting customers with an opportunity to better manage input costs, logistics, and environmental impact. RPD® printed parts are already flying on commercial aircraft, and Norsk Titanium has gained significant traction with large defense and industrial customers.
www.norsktitanium.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005812/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corona Global Named Most Valuable Beer Brand in Kantar BrandZ Rankings for Second Consecutive Year15.5.2025 06:01:00 CEST | Press release
Michelob ULTRA Moves Into Top 5 Most Valuable Beer Brands GloballyAB InBev Brands Represent 8 of the Top 10 Most Valuable Beer Brands Globally Corona has been recognized as the most valuable beer brand in the world for the second consecutive year in Kantar's BrandZ 2025 Most Valuable Global Brands report, released today. Eight out of the 10 most valuable global beer brands belong to AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), according to the report ranking the top brands in the world. In 2024 AB InBev produced all-time high revenue and 15% Underlying EPS growth. The year marked double-digit growth for Corona outside of its home market of Mexico and triple-digit growth of its no-alcohol brand Corona Cero. Corona Cero is the first beer brand to sponsor the Olympic Games making its debut in Paris 2024. In 2025, Corona is celebrating its 100-year anniversary with events all over the world through its “Corona 100” platform. Corona is followed by Budweiser, the second most valuab
Forrester Opens Nominations For Its 2025 B2B Awards In EMEA And APAC15.5.2025 06:00:00 CEST | Press release
Awards honor B2B organizations that drive revenue growth through effective alignment of marketing, sales, and product strategies Forrester (Nasdaq: FORR) today opened calls for nominations for its 2025 B2B Return On Integration Honors and B2B Programs Of The Year Awards in Asia Pacific (APAC) and Europe, Middle East, and Africa (EMEA). These awards will recognize B2B organizations based in both regions for achieving functional excellence and outstanding alignment across marketing, sales, and product — the B2B revenue engine — to improve customer experience and drive growth. Nominations for both award categories are open to organizations of all sizes in each region. B2B leaders across APAC and EMEA — including chief marketing officers, chief sales officers, chief product officers, and other marketing, sales, and product leaders — are invited and encouraged to apply. To be eligible, programs need to be developed by leaders and teams based in the APAC or EMEA regions. The nomination crite
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 04:12:00 CEST | Press release
Results at a glance:71.4% of MetaXplore™ reports from 4,616 patients identified actionable results41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often g
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 04:00:00 CEST | Press release
Optimizing Global Websites for the Japanese Visitors: Detailed UX/UI Adaptation, Comprehensive Japanese Localization, Extensive Localization and Cultural Relevance to Fit the Local Audience. Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 03:11:00 CEST | Press release
Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom